Lumida
/AMPH
⌘K
Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

AMPH
$19.75USD↓-0.58%-0.11 today

MARKET CAP

870.6M

P/E (TTM)

6.8x

FWD P/E

6.3x

DAY RANGE

$20 – $20

52W RANGE

$17
$31

AI Summary

Stalk
StalkMedium

AMPH is in a Stage 1 early consolidation after a terminal decline, trading in a tight range around its short EMAs and 50 DMA. Mean-reversion eligibility and strong free-cash-flow metrics support a tactical bounce from the well-defended demand zone, consistent with the Free Cash Flow + Buybacks strategy’s emphasis on high-quality entry points. However, indicators and volume remain neutral with no clear timing edge. Execution should be patient for pullback-based entries near support.

  • ↑High earnings yield (2.2%) and book-to-price ratio (1.92) signal deep value.
  • ↑FDA approved ipratropium bromide HFA generic inhaler, first mover in segment.
  • ↓Gross margin contracted from 50% in Q1’25; glucagon revenues down 27% YoY.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Amphistar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company based in the United States that specializes in the development, manufacturing, and commercialization of specialty pharmaceuticals, particularly focusing on complex injectables and proprietary products. As a key player in the competitive landscape, Amphistar is positioned in the healthcare and biotechnology sectors, particularly in the areas of respiratory therapies and injectables. The company has seen consistent revenue growth driven by innovative product launches, while also navigating various industry challenges, including pricing pressures and increasing competition.

Bull says

  • ↑High earnings yield (2.2%) and book-to-price ratio (1.92) signal deep value.
  • ↑FDA approved ipratropium bromide HFA generic inhaler, first mover in segment.
  • ↑$29.5M share repurchases in Q1’26 (3% of shares) reflect management confidence.
  • ↑Vaximi vaccine sales jumped 21% YoY, driving segment growth momentum.
  • ↑Robust $300M cash and short-term investments fund R&D and expansions.
  • ↑Elevated leverage supports strategic growth investments; profitability remains solid.

Bear says

  • ↓Gross margin contracted from 50% in Q1’25; glucagon revenues down 27% YoY.
  • ↓R&D expenses rose 33% YoY to $26.7M, weighing on operating margins.
  • ↓Negative analyst growth and revision trends signal eroding future earnings confidence.
  • ↓Minimal hedge fund ownership reflects weak institutional interest in the stock.
  • ↓Vaximi vaccine revenues fell 15% YoY to $32.4M, highlighting competitive headwinds.
  • ↓Regulatory hurdles and generic competition threaten pipeline approvals and market share.

Investment themes with AMPH

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026bullish

Transcript signals

Bull points

  • $171.2 million for the first quarter, reflecting a return to growth, driven primarily by contributions from recent product launches, while overall performance across the base business remains stable.
  • deploy capital towards initiatives that we believe will drive long-term growth.
  • Demand trends remain positive, with U.S. sales unit volumes increasing approximately 8% year over year.

Bear points

  • Net income decreased to $6.4 million or 14 cents per share in the first quarter from $25.3 million or 51 cents per share in the first quarter of 2025.
  • Adjusted net income decreased to $19.5 million or 42 cents per share compared to an adjusted net income of $36.9 million or 74 cents per share in the first quarter of last year.
Read full transcript analysis ›